lovastatin has been researched along with Liver Neoplasms in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.52) | 18.7374 |
| 1990's | 29 (69.05) | 18.2507 |
| 2000's | 4 (9.52) | 29.6817 |
| 2010's | 4 (9.52) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Baader, E; Bartmann, W; Beck, G; Bergmann, A; Granzer, E; Jendralla, H; Kesseler, K; Krause, R; Schacht, U; von Kerekjarto, B | 1 |
| Baader, E; Bartmann, W; Beck, G; Bergmann, A; Granzer, E; Jendralla, H; Kesseler, K; Krause, R; Schubert, W; von Kerekjarto, B | 1 |
| Draper, CD; Hutson, JL; Inglis, GG; Procopiou, PA; Ross, BC; Watson, NS | 1 |
| Connolly, PJ; Loughney, DA; Minor, LK; Westin, CD | 1 |
| Ashton, MJ; Brown, TJ; Fenton, G; Halley, F; Harper, MF; Lockey, PM; Porter, B; Roach, AG; Stuttle, KA; Vicker, N; Walsh, RJ | 1 |
| Fu, R; Lou, D; Ma, X; Wu, F; Zhang, X; Zheng, D | 1 |
| Beeson, CC; Beeson, GC; Christie, CF; Fang, D; Heslop, KA; Hunt, EG; Maldonado, EN; Morris, ME; Rovini, A | 1 |
| Cheng, Z; Fu, SW; Hu, B; Ruan, LY; Wang, Y; Zheng, JN; Zheng, MH; Zhou, YY; Zhu, GQ | 1 |
| Popovich, DG; Tiaras, F; Yeo, CR; Zhang, W | 1 |
| Dandri, M; Kah, J; Keller, AD; Montalbano, R; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Volz, T; Wüstenberg, A | 1 |
| Dong, J; Fujii, S; Furumoto, T; Goto, D; Imagawa, S; Kaneko, T; Kitabatake, A; Mishima, T; Nakai, Y; Zaman, TA | 1 |
| Dong, J; Fujii, S; Furumoto, T; Goto, D; Imagawa, S; Kitabatake, A; Li, H; Nakabayashi, H; Nishi, S; Sakai, M; Zaman, TA | 1 |
| Marks, B; Raucy, J; Trubetskoy, O; Yueh, MF; Zielinski, T | 1 |
| Buchwald, H; Furcht, LL; Morris, TJ; Palm, SL | 1 |
| Conrad, DG; Jiang, G; McKenzie, TL; Shechter, I | 1 |
| Hrboticky, N; Lux, I; Tang, L; Weber, PC; Zimmer, B | 1 |
| Stephan, ZF; Yurachek, EC | 1 |
| Clark, RW; Gordon, DA; Parker, RA; Pearce, BC; Wright, JJ | 1 |
| Illingworth, R | 1 |
| Pahor, M | 1 |
| Crick, DC; Feller, DR; Henry, KW; Noonan, DJ; O'Brien, ML; Rangwala, SM; Waechter, CJ; Weinberger, C | 1 |
| Bentzen, C; Berkhout, TA; Jackson, B; Niesor, E; Patel, DD; Simon, HM; Suckling, KE | 1 |
| Blegen, H; Carlberg, M; Dricu, A; Hjertman, M; Höög, A; Larsson, O; Wang, M; Zickert, P | 1 |
| Ku, EC | 1 |
| Branch, SK; Broitman, SA; Cerda, S; Wilkinson, J | 1 |
| Galli, C; Marangoni, F; Petroni, A; Risé, P; Visioli, F | 1 |
| Cohen, SA; Doerr, RJ; Hordines, J; Mehta, N; Sykes, D | 1 |
| Joseph, SB; Kast, HR; Laffitte, BA; Mangelsdorf, DJ; Repa, JJ; Tontonoz, P; Wilpitz, DC | 1 |
| Hidaka, Y; Horie, M; Hotta, H; Iwasawa, Y; Kamei, T; Nagata, Y | 1 |
| Adams, JL; Berkhout, TA; Bossard, MJ; Mayer, RJ | 1 |
| Cianflone, KM; Rodriguez, MA; Sniderman, AD; Vas, D; Yasruel, Z | 1 |
| Hidaka, Y; Kamei, T; Satoh, T | 1 |
| Elliott, JD; Fisher, M; Leber, J; Louis-Flamberg, P; Mayer, RJ | 1 |
| Antonov, AS; Fuki, IV; Kosykh, VA; Pavlov, MY; Podrez, EA; Repin, VS; Safonova, IG; Sviridov, DD | 1 |
| Ferguson, E; Krause, BR; Newton, RS; Roth, BD; Shaw, MK; Sliskovic, DR | 1 |
| Hidaka, Y; Ishida, F; Kamei, T; Nagata, Y | 1 |
| Brocia, RW; Fisher, EA; Williams, KJ | 1 |
| Barnhart, RL; Busch, SJ; Flanagan, MA; Jackson, RL; Martin, GA | 1 |
| Cohen, LH; Griffioen, M; van Miert, E | 1 |
| Cimis, GM; Molowa, DT | 1 |
| Cohen, LH; Griffioen, M | 1 |
| Boogaard, A; Cohen, LH; Griffioen, M | 1 |
2 review(s) available for lovastatin and Liver Neoplasms
| Article | Year |
|---|---|
Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Liver Neoplasms; Lovastatin; Simvastatin | 2024 |
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Topics: Atorvastatin; Bayes Theorem; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Neoplasms; Lovastatin; Observational Studies as Topic; Pravastatin; Pyridines; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2016 |
40 other study(ies) available for lovastatin and Liver Neoplasms
| Article | Year |
|---|---|
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Topics: Animals; Anticholesteremic Agents; Caproates; Carcinoma, Hepatocellular; Cholesterol; Dogs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Liver; Liver Neoplasms; Lovastatin; Male; Molecular Structure; Rabbits; Rats; Structure-Activity Relationship; Tumor Cells, Cultured | 1991 |
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Topics: Animals; Anticholesteremic Agents; Carcinoma, Hepatocellular; Chemical Phenomena; Chemistry; Cholesterol; Dogs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Neoplasms; Lovastatin; Male; Molecular Structure; Pyrroles; Rabbits; Rats; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors.
Topics: Carcinoma, Hepatocellular; Cholesterol; Humans; Hydroxy Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Molecular Structure; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts.
Topics: Acetates; Animals; Carcinoma, Hepatocellular; Cholesterol; Hydroxy Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indazoles; Liver; Liver Neoplasms; Lovastatin; Models, Molecular; Molecular Structure; Rats; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
New low-density lipoprotein receptor upregulators acting via a novel mechanism.
Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Humans; Indicators and Reagents; Liver; Liver Neoplasms; Lovastatin; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Parabens; Phenylenediamines; Receptors, LDL; Structure-Activity Relationship; Transcription, Genetic; Tumor Cells, Cultured; Up-Regulation | 1996 |
Statin-dependent modulation of mitochondrial metabolism in cancer cells is independent of cholesterol content.
Topics: Adenocarcinoma of Lung; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria, Liver; Simvastatin | 2019 |
Lovastatin interacts with natural products to influence cultured hepatocarcinoma cell (hep-g2) growth.
Topics: Antineoplastic Agents; Capsaicin; Carcinoma, Hepatocellular; Catechin; Cell Line, Tumor; Cells, Cultured; Curcumin; Drug Synergism; Hep G2 Cells; Herb-Drug Interactions; Humans; Liver Neoplasms; Lovastatin; Plant Extracts | 2010 |
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Suppressor Protein p53 | 2012 |
Increased expression of plasminogen activator inhibitor-1 by mediators of the acute phase response: a potential progenitor of vasculopathy in hypertensives.
Topics: Acute-Phase Reaction; Blotting, Northern; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Interleukin-1; Interleukin-6; Liver Neoplasms; Lovastatin; Mevalonic Acid; Plasminogen Activator Inhibitor 1; RNA, Messenger; Up-Regulation | 2003 |
Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-delta.
Topics: Animals; Atherosclerosis; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Protein-delta; Cell Line, Tumor; Cell Nucleus; Chromosome Mapping; Gene Expression; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred ICR; Mutagenesis, Site-Directed; Plasminogen Activator Inhibitor 1; Promoter Regions, Genetic; Response Elements; RNA, Messenger; Thrombosis; Transfection | 2005 |
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Clotrimazole; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dimethyl Sulfoxide; Enhancer Elements, Genetic; Enzyme Induction; Genes, Reporter; Genes, Synthetic; Humans; Ketoconazole; Liver Neoplasms; Lovastatin; Luciferases; Mifepristone; Neoplasm Proteins; Nifedipine; Omeprazole; Paclitaxel; Phenytoin; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Recombinant Fusion Proteins; Rifampin; Thiazolidinediones; Transcription, Genetic; Troglitazone; Troleandomycin | 2005 |
Effect of lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth.
Topics: Animals; Carcinoma, Hepatocellular; Cell Adhesion; Cell Division; Chemotherapy, Adjuvant; Cholesterol; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Humans; Liver Neoplasms; Lovastatin; Mitomycin; Rats; Tumor Cells, Cultured | 1995 |
Transcriptional regulation by lovastatin and 25-hydroxycholesterol in HepG2 cells and molecular cloning and expression of the cDNA for the human hepatic squalene synthase.
Topics: Amino Acid Sequence; Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Division; Cloning, Molecular; DNA, Neoplasm; Farnesyl-Diphosphate Farnesyltransferase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Kinetics; Liver; Liver Neoplasms; Lovastatin; Molecular Sequence Data; Oligodeoxyribonucleotides; Polymerase Chain Reaction; Rats; RNA; RNA, Messenger; Sequence Homology, Amino Acid; Transcription, Genetic; Tumor Cells, Cultured | 1993 |
Lovastatin increases arachidonic acid levels and stimulates thromboxane synthesis in human liver and monocytic cell lines.
Topics: Analysis of Variance; Arachidonic Acid; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Cholesterol Esters; Fatty Acids; Humans; Kinetics; Linoleic Acid; Linoleic Acids; Liver; Liver Neoplasms; Lovastatin; Monocytes; Phospholipids; Thromboxanes; Triglycerides; Tumor Cells, Cultured | 1994 |
Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL.
Topics: Binding, Competitive; Carbocyanines; Carcinoma, Hepatocellular; Fluorescent Dyes; Humans; Hydroxycholesterols; Iodine Radioisotopes; Lipoproteins, LDL; Liver Neoplasms; Lovastatin; Receptors, LDL; Tumor Cells, Cultured | 1993 |
Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Acetates; Acetic Acid; Androstenes; Animals; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cell Line; Chickens; CHO Cells; Cholesterol; Chromans; Cricetinae; Gene Expression Regulation, Enzymologic; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Ketoconazole; Kinetics; Liver Neoplasms; Liver Neoplasms, Experimental; Lovastatin; Mevalonic Acid; Rats; RNA Processing, Post-Transcriptional; RNA, Messenger; Suppression, Genetic; Tritium; Tumor Cells, Cultured; Vitamin E | 1993 |
Carcinogenicity of lipid-lowering drugs.
Topics: Acyl Coenzyme A; Gemfibrozil; Humans; Hypolipidemic Agents; Liver; Liver Neoplasms; Lovastatin | 1996 |
Carcinogenicity of lipid-lowering drugs.
Topics: Acyl Coenzyme A; Animals; Enzyme Inhibitors; Humans; Hypolipidemic Agents; Liver; Liver Neoplasms; Lovastatin | 1996 |
Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis.
Topics: Acyl-CoA Oxidase; Animals; Anticholesteremic Agents; Cholesterol; Farnesol; Fatty Acids, Unsaturated; Liver Neoplasms; Lovastatin; Microbodies; Oxidoreductases; Polyisoprenyl Phosphates; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Sesquiterpenes; Transcription Factors | 1996 |
The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Acetates; Anticholesteremic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Diphosphonates; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Kinetics; Lanosterol; Lipoproteins, LDL; Liver Neoplasms; Lovastatin; Receptors, LDL; RNA, Messenger; Transcription, Genetic; Tritium; Tumor Cells, Cultured | 1996 |
Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth.
Topics: Base Sequence; Cell Division; Cell Line; Cell Membrane; Colonic Neoplasms; DNA Primers; DNA, Neoplasm; Dolichol Phosphates; Enzyme Inhibitors; Gene Expression; Glycosylation; Growth Substances; Hepatoblastoma; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin-Like Growth Factor I; Kinetics; Liver Neoplasms; Lovastatin; Melanoma; Mevalonic Acid; Models, Biological; Molecular Sequence Data; Oligonucleotides, Antisense; Protein Processing, Post-Translational; Receptor, IGF Type 1; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 1996 |
Regulation of fatty acid biosynthesis by intermediates of the cholesterol biosynthetic pathway.
Topics: Anticholesteremic Agents; Carboxy-Lyases; Carcinoma, Hepatocellular; Cholesterol; Fatty Acids; Homeostasis; Humans; Kinetics; Liver Neoplasms; Lovastatin; Mevalonic Acid; Structure-Activity Relationship; Tumor Cells, Cultured | 1996 |
Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Cyclohexenes; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Limonene; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred BALB C; Monoterpenes; Protein Prenylation; Terpenes; Tumor Cells, Cultured | 1996 |
Manipulation of the fate of long chain polyunsaturated fatty acids in cultured cells.
Topics: Arachidonic Acid; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line; Cholesterol; Enzyme Inhibitors; Ethanol; Fatty Acids, Unsaturated; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linoleic Acid; Linoleic Acids; Liver Neoplasms; Lovastatin; Mevalonic Acid; Monocytes; Neuroblastoma; Simvastatin; Tumor Cells, Cultured | 1997 |
Low density lipoproteins and Lovastatin modulate the organ-specific transendothelial migration of primary and metastatic human colon adenocarcinoma cell lines in vitro.
Topics: Adenocarcinoma; Animals; Cell Adhesion; Cell Movement; Colonic Neoplasms; Endothelium, Vascular; Humans; Lipoproteins, LDL; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred BALB C; Organ Specificity; Time Factors; Tumor Cells, Cultured | 1998 |
LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Anticholesteremic Agents; Apolipoproteins E; Arteriosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Cell Differentiation; Cells, Cultured; Cholesterol; Diet, Atherogenic; Dimerization; DNA-Binding Proteins; Enhancer Elements, Genetic; Gene Expression Regulation; Humans; Hydrocarbons, Fluorinated; Hydroxycholesterols; Ligands; Lipids; Liver Neoplasms; Liver X Receptors; Lovastatin; Macrophages, Peritoneal; Male; Mevalonic Acid; Mice; Mice, Knockout; Organic Chemicals; Orphan Nuclear Receptors; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoid X Receptors; RNA, Messenger; Sulfonamides; Tetradecanoylphorbol Acetate; Transcription Factors; Tumor Cells, Cultured | 2001 |
Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells.
Topics: Acetates; Anticholesteremic Agents; Benzylamines; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Cycloheximide; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins, LDL; Liver Neoplasms; Lovastatin; Mevalonic Acid; Nucleic Acid Hybridization; Oxygenases; RNA, Neoplasm; Simvastatin; Squalene Monooxygenase; Thiophenes | 1991 |
Effects of a novel lanosterol 14 alpha-demethylase inhibitor on the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in Hep G2 cells.
Topics: Carcinoma, Hepatocellular; Cell-Free System; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Humans; Hydroxymethylglutaryl CoA Reductases; Lanosterol; Liver Neoplasms; Lovastatin; Mevalonic Acid; Oxidoreductases; Receptors, LDL; Sterol 14-Demethylase; Sterols; Tumor Cells, Cultured | 1991 |
Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge.
Topics: Apolipoproteins B; Blood Proteins; Carcinoma, Hepatocellular; Cholesterol Esters; Complement C3a; Fatty Acids; Humans; Kinetics; Liver; Liver Neoplasms; Lovastatin; Oleic Acids; Progesterone; Sterol O-Acyltransferase; Triglycerides; Tumor Cells, Cultured | 1990 |
Regulation of squalene epoxidase in HepG2 cells.
Topics: Binding, Competitive; Carcinoma, Hepatocellular; Cholesterol; Detergents; Enzyme Induction; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins, LDL; Liver; Liver Neoplasms; Lovastatin; Mevalonic Acid; Microsomes, Liver; Octoxynol; Oxygenases; Polyethylene Glycols; Simvastatin; Squalene Monooxygenase; Tumor Cells, Cultured | 1990 |
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A synthase by antibiotic 1233A and other beta-lactones.
Topics: Acetates; Animals; Anti-Bacterial Agents; Carcinoma, Hepatocellular; Cell Line; Cholestyramine Resin; Fatty Acids, Unsaturated; Humans; Hydroxymethylglutaryl-CoA Synthase; Kinetics; Lactones; Liver; Liver Neoplasms; Lovastatin; Molecular Structure; Oxo-Acid-Lyases; Rats; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Inhibition of cholesterol synthesis by lovastatin tested on six human cell types in vitro.
Topics: Anticholesteremic Agents; Carcinoma, Hepatocellular; Cells, Cultured; Cholesterol; Dose-Response Relationship, Drug; Fibroblasts; Humans; Intestinal Mucosa; Intestines; Liver; Liver Neoplasms; Lovastatin; Muscle, Smooth, Vascular; Receptors, LDL; Tumor Cells, Cultured | 1990 |
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Lovastatin; Male; Naphthalenes; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tumor Cells, Cultured | 1990 |
Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells.
Topics: Anticholesteremic Agents; Carcinoma, Hepatocellular; Cholesterol; Cholesterol Esters; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Progesterone; Receptors, LDL; Simvastatin; Tumor Cells, Cultured | 1990 |
The unstirred water layer as a site of control of apolipoprotein B secretion.
Topics: Antibodies; Apolipoproteins B; Carcinoma, Hepatocellular; Cell Line; Culture Media; Dideoxyadenosine; Humans; Liver Neoplasms; Lovastatin; Receptors, LDL; Water | 1990 |
Differential regulation of hepatic triglyceride lipase and 3-hydroxy-3-methylglutaryl-CoA reductase gene expression in a human hepatoma cell line, HepG2.
Topics: Carcinoma, Hepatocellular; Cell Line; Cholesterol; Gene Expression Regulation; Hydroxymethylglutaryl CoA Reductases; Kinetics; Lipase; Liver Neoplasms; Lovastatin; Mevalonic Acid; RNA Probes; RNA, Messenger; Transcription, Genetic | 1990 |
Regulation of squalene synthetase in human hepatoma cell line Hep G2 by sterols, and not by mevalonate-derived non-sterols.
Topics: Androstenes; Carcinoma, Hepatocellular; Cholesterol; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Transferases; Isomerases; Lipoproteins, HDL; Lipoproteins, LDL; Liver Neoplasms; Lovastatin; Mevalonic Acid; Oxidoreductases; Sterols; Tumor Cells, Cultured | 1989 |
Co-ordinate regulation of low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase and synthase gene expression in HepG2 cells.
Topics: Carcinoma, Hepatocellular; DNA, Neoplasm; Gene Expression Regulation; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Synthase; Liver Neoplasms; Lovastatin; Mevalonic Acid; Oxo-Acid-Lyases; Receptors, LDL; RNA, Messenger; Tumor Cells, Cultured | 1989 |
Regulation of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA contents in human hepatoma cell line Hep G2 by distinct classes of mevalonate-derived metabolites.
Topics: Androstenes; Anticholesteremic Agents; Carcinoma, Hepatocellular; Cell Line; Enzyme Activation; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Immunoblotting; Lipoproteins, LDL; Liver Neoplasms; Lovastatin; Mevalonic Acid; RNA, Messenger; Tumor Cells, Cultured | 1988 |
Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in human hepatoma cell line Hep G2. Effects of inhibitors of cholesterol synthesis on enzyme activity.
Topics: Androstenes; Animals; Anticholesteremic Agents; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Imidoesters; Lipid Metabolism; Liver Neoplasms; Lovastatin; Mevalonic Acid; Naphthalenes; Triparanol | 1987 |